CN104258282A - 一种肉鸡的养殖所使用的药物的制造方法 - Google Patents
一种肉鸡的养殖所使用的药物的制造方法 Download PDFInfo
- Publication number
- CN104258282A CN104258282A CN201410496358.8A CN201410496358A CN104258282A CN 104258282 A CN104258282 A CN 104258282A CN 201410496358 A CN201410496358 A CN 201410496358A CN 104258282 A CN104258282 A CN 104258282A
- Authority
- CN
- China
- Prior art keywords
- radix
- broiler
- powder
- semen
- protective agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title abstract description 7
- 238000009395 breeding Methods 0.000 title abstract description 4
- 230000001488 breeding effect Effects 0.000 title abstract description 4
- 210000000582 semen Anatomy 0.000 claims abstract description 42
- 239000000843 powder Substances 0.000 claims abstract description 22
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims abstract description 9
- 229960000723 ampicillin Drugs 0.000 claims abstract description 9
- 229920000881 Modified starch Polymers 0.000 claims abstract description 7
- 239000004368 Modified starch Substances 0.000 claims abstract description 7
- 235000019426 modified starch Nutrition 0.000 claims abstract description 7
- 230000005855 radiation Effects 0.000 claims abstract description 3
- 239000003223 protective agent Substances 0.000 claims description 30
- 241000208340 Araliaceae Species 0.000 claims description 10
- 241000233835 Tradescantia Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229920003091 Methocel™ Polymers 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 abstract description 22
- 230000003187 abdominal effect Effects 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 6
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 3
- 238000002386 leaching Methods 0.000 abstract 2
- 240000008027 Akebia quinata Species 0.000 abstract 1
- 235000007756 Akebia quinata Nutrition 0.000 abstract 1
- 241000233839 Commelina communis Species 0.000 abstract 1
- 241000037740 Coptis chinensis Species 0.000 abstract 1
- 241000131458 Elsholtzia Species 0.000 abstract 1
- 241000221079 Euphorbia <genus> Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 235000005206 Hibiscus Nutrition 0.000 abstract 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 abstract 1
- 244000048199 Hibiscus mutabilis Species 0.000 abstract 1
- 235000003973 Hibiscus mutabilis Nutrition 0.000 abstract 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 abstract 1
- 235000010254 Jasminum officinale Nutrition 0.000 abstract 1
- 240000005385 Jasminum sambac Species 0.000 abstract 1
- 244000207740 Lemna minor Species 0.000 abstract 1
- 235000006439 Lemna minor Nutrition 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 abstract 1
- 235000012874 Phaseolus calcaratus Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000001417 Vigna umbellata Species 0.000 abstract 1
- 235000011453 Vigna umbellata Nutrition 0.000 abstract 1
- 240000000038 Ziziphus mauritiana Species 0.000 abstract 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 abstract 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 abstract 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 32
- 230000035611 feeding Effects 0.000 description 27
- 206010003445 Ascites Diseases 0.000 description 22
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000002601 urease inhibitor Substances 0.000 description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 229930003268 Vitamin C Natural products 0.000 description 16
- 235000019154 vitamin C Nutrition 0.000 description 16
- 239000011718 vitamin C Substances 0.000 description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- 239000002671 adjuvant Substances 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 12
- 206010021143 Hypoxia Diseases 0.000 description 10
- 206010025482 malaise Diseases 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 244000046052 Phaseolus vulgaris Species 0.000 description 9
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 9
- 208000004880 Polyuria Diseases 0.000 description 9
- 229910000019 calcium carbonate Inorganic materials 0.000 description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000035619 diuresis Effects 0.000 description 9
- 239000008157 edible vegetable oil Substances 0.000 description 9
- 239000010419 fine particle Substances 0.000 description 9
- 235000013360 fish flour Nutrition 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 239000004575 stone Substances 0.000 description 9
- 206010002660 Anoxia Diseases 0.000 description 8
- 241000976983 Anoxia Species 0.000 description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 230000007953 anoxia Effects 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 230000000378 dietary effect Effects 0.000 description 8
- 239000004459 forage Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000019691 monocalcium phosphate Nutrition 0.000 description 5
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000036284 oxygen consumption Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 4
- 229940090496 Urease inhibitor Drugs 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 description 4
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 239000000052 vinegar Substances 0.000 description 4
- 235000021419 vinegar Nutrition 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 210000001147 pulmonary artery Anatomy 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 201000006306 Cor pulmonale Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 208000005228 Pericardial Effusion Diseases 0.000 description 2
- 241000222640 Polyporus Species 0.000 description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000019713 millet Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008427 tissue turnover Effects 0.000 description 2
- 210000000051 wattle Anatomy 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241001480233 Paragonimus Species 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了一种肉鸡的养殖所使用的药物的制造方法,其中,按如下步骤操作:将葶苈子、大枣、黄连、栀子,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶,木通、生地、人参、麦冬、京大戟、赤小豆,桔梗、炙甘草使用水浸提法浸提三次,三次浸提液合并后,蒸煮至粘稠状,加入改性淀粉和羟甲基纤维素、矫味剂;干燥后呈粉剂并过80目筛,过筛后的粉剂经过紫外照射消毒10秒后,加入氨苄青霉素,加入的氨苄青霉素的质量为粉剂质量的1-2%,混合均匀后制得本发明所用的防治药物。本发明配比简单,使用方便,预防和防治肉鸡腹水症效果好,能够明显降低因此病症给养殖户带来的损失。
Description
技术领域:
本发明涉及药物技术领域,尤其涉及一种肉鸡的养殖所使用的药物的制造方法。
背景技术:
肉鸡的养殖过程中,容易因为腹水症导致鸡禽大批死亡,给养殖户造成重大损失。这种病症一般在15-20天时是感染高峰期。肉鸡腹水症,(Ascites syndrome, AS),又称肺动脉高压综合征(Pulmonary hypertension syndrome, PHS),是以右心肥大-腹水形成为特征的主要发生于商品代肉仔鸡的一种综合征侯群。最初(70年代至80年代中期)主要报道于高海拔缺氧地区,近十年来在低海拔地区有关该病的报道也日趋增多,严重危害着我国的肉鸡养殖业。肉鸡腹水症的诱发因素:绝对缺氧 高海拔地区的氧分压低,肉仔鸡因大气性缺氧使AS的发病率大幅度提高。钙、磷代谢障碍时的胸廓变形和呼吸系统严重的霉菌感染时,可因呼吸性缺氧而使AS的发病率升高。相对缺氧: 喂颗粒料时因快速增重可使AS发病率明显增加。雄性肉鸡代谢率较高,需氧量大,AS发病率高。寒冷使动物耗氧量增加(试验表明,7℃时肉仔鸡耗氧量比23℃时增加93%),AS的发病率会大幅度增加。 肉鸡本身的因素是AS发生的基础: AS是现代商品代肉仔鸡结构与机能矛盾的产物。肉鸡的遗传选择过去主要集中在产肉性能,饲料报酬和生长速度等方面,而忽视了对各个器官协调发展的关注,结果导致商品代肉仔鸡的呼吸和循环系统对缺氧、寒冷等不良环境刺激的适应性大为降低。特别是常因右心负荷增加诱发右心肥大和衰竭—腹水综合征。如肉仔鸡的肺系数(肺重/体重)只有同龄蛋鸡的60%,故其对缺氧的代偿适应能力较低;在寒冷和缺氧的刺激下,心肌易发生损伤(特异性反映心脏结构损害的心肌蛋白TNT的释放量增加)。这种因素在平原地区养殖鸡禽的主要原因。如:饲粮浓度过高,生长过快,对氧气的需求增加而导致缺氧,引起腹水综合征的发生;饲料中的钠盐含量过高,会使机体组织细胞与血液间的渗透压明显加大体液调节机能减弱,从而导致腹水综合征的发生。AS的临床症状及病理变化可概括三个方面:(1) 全身瘀血及瘀血性肝营养不良(肝硬化)。AS患鸡典型的临床症状是腹部膨大,腹部皮肤发亮,用手触压时有波动感,病鸡被毛蓬松,不愿站立,行动缓慢,似企鹅状走动。呼吸困难,严重病例鸡冠,肉髯呈紫红色,皮肤发绀。剖检可见肝脏瘀血、肿大及纤维性硬化,腹腔积有大量的清亮或稻草色液体,液体中可混有纤维素块或絮状物。(2) 右心脏肥大,扩张,心瓣膜出现病理性改变。(3) 肺脏瘀血水肿。这些都是肺源性心脏病的典型特征。因此,目前一般以肺源性心脏病的发病机制解释AS的发病环节:即诱发因素→肺动脉高压(即右心负荷增加)→右心肥大和衰竭→全身瘀血及瘀血性肝营养不良,后腔静脉回流受阻及腹水形成。
为避免这种病症,现有的养殖方法中,通常采用如下手段:1、每100千克饲料中添加含硒生长素500克,并适量添加维生素E。这种补充微量元素的方法,预防效果好,但是对于已经发病的则救治不及。2 对病重者可用双氢克尿噻每只鸡半片、维生素C 10毫克灌服。对鸡群可用双氢克尿噻片100毫克,加葡萄糖125克,混合后加水20千克,每日2次,连服3天,使用16号针头对腹水明显的病鸡进行腹腔穿刺,放出积液,可使死亡时间推迟2~4天。这种方法只能推至死亡时间,为救治肉鸡留下时间而已。3、中药方剂用二丑、泽泻、木通、商陆根、苍术、猪苓、谷子、灯心草各500克,竹叶250克,共研细末,每只鸡每次喂服1克,连用3天。这种方法对于肉鸡腹水症是有一定效果的,但是,经过试验发现,有效率仅为60%上下,即效果不足。
本发明在现有技术的基础上,旨在提供一种配比简单,使用方便,预防和防治肉鸡腹水症效果好,能够明显降低因此病症给养殖户带来的损失的肉鸡的养殖所使用的药物的制造方法。
发明内容:
本发明的目的在于克服现有技术中存在的缺点,提供一种配比简单,使用方便,预防和防治肉鸡腹水症效果好,能够明显降低因此病症给养殖户带来的损失的肉鸡的养殖所使用的药物的制造方法。
为了实现上述目的,本发明提供了一种肉鸡的养殖所使用的药物的制造方法,其中,按照如下步骤操作:
A肉鸡在15-28日龄期间内,饲料供应量减少15%;28日龄后恢复正常的饲料供应量,
B整个养殖期间保持鸡舍通风,减少鸡舍内部CO2和NH3的含量,
C日常喂食的饲料中磷含量不小于0.05%,盐含量不大于0.5%,尿酶抑制剂含量不小于0.13%,碳酸氢钠含量不小于1%,维生素C不小于0.5%;
D肉鸡在15-28日龄期间内,添加的防治药物的含量不小于3%,发病期间,添加的防治药物的含量不小于5%。
所述防治药物的组分为:葶苈子、大枣、黄连、栀子各50-80g,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶各40-50g,木通、生地、人参、麦冬、京大戟、赤小豆各20-40g,桔梗、炙甘草各10-30g。
所述防治药物的组分为:葶苈子、大枣、黄连、栀子各50-70g,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶各40-45g,木通、生地、人参、麦冬、京大戟、赤小豆各20-30g,桔梗、炙甘草各10-20g。
所述防治药物的组分为:葶苈子、大枣、黄连、栀子各70-80g,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶各45-50g,木通、生地、人参、麦冬、京大戟、赤小豆各30-40g,桔梗、炙甘草各20-30g。
饲料的组分为:玉米54-61%,豆粕27-32%,碳酸轻钙1-1.5%,石粉1-1.2%,食用油2-3%,鱼粉2-3%,麦麸3-5%,贝壳粉2-3%。
步骤C中所述日常喂食的饲料中磷含量不小于0.05%添加的磷元素成分为磷酸氢钙、磷酸二氢钙或过磷酸钙中的任一一种或几种。
步骤C中所述尿酶抑制剂优选为醋羟氨酸。
防治药物的制备方法:将葶苈子、大枣、黄连、栀子,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶,木通、生地、人参、麦冬、京大戟、赤小豆,桔梗、炙甘草使用水浸提法浸提三次,三次浸提液合并后,蒸煮至粘稠状,加入改性淀粉和羟甲基纤维素、矫味剂;改性淀粉和羟甲基纤维素、矫味剂的质量比为2:1:0.5,改性淀粉、羟甲基纤维素与矫味剂的质量和为防治药物原料(葶苈子、大枣、黄连、栀子,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶,木通、生地、人参、麦冬、京大戟、赤小豆,桔梗、炙甘草)的质量的2-3%。干燥后呈粉剂并过80目筛,过筛后的粉剂经过紫外照射消毒10秒后,加入氨苄青霉素,加入的氨苄青霉素的质量为粉剂质量的1-2%,混合均匀后制得本发明所用的防治药物。
这种防治药物,以泻肺行水的对药葶苈子、大枣,清肺解氨苄青霉素毒的对药黄连、栀子为君药,以化瘀利尿的蒲黄、活血化瘀的郁金、利水化瘀的泽兰、化湿利水的香薷、退热的浮萍、鸭趾草、解毒的木芙蓉叶为臣药,以清心利尿的对药木通、生地、益气敛阴的对药人参、麦冬,逐水的京大戟,利水渗湿的赤小豆为佐药,以通经的桔梗和甘草为使药。经过浸提法提取有效成分后,与消炎药物氨苄青霉素混合,加强防治效果。
饲料的制造方法:
饲料基本料:玉米54-61%,豆粕27-32%,碳酸轻钙1-1.5%,石粉1-1.2%,食用油2-3%,鱼粉2-3%,麦麸3-5%,贝壳粉2-3%。
辅料:磷酸氢钙、磷酸二氢钙或过磷酸钙中的任一一种或几种;盐、尿酶抑制剂、碳酸氢钠、维生素C、防治药物。
例如:
饲料:玉米54.2%,豆粕32%,碳酸轻钙1.2%,石粉1%,食用油2%,鱼粉3%,麦麸4%,贝壳粉2.6%。
辅料的添加量为均以饲料为参照基础。
例如,饲料基本料配置100kg,加入辅料,加入的辅料为过磷酸钙0.06kg,盐0.4kg,尿酶抑制剂0.15kg,碳酸氢钠1kg,维生素C0.6kg,防治药物3.5kg。
维生素C可以用复合多维素替代。
本发明的优点为:配比简单,使用方便,预防和防治肉鸡腹水症效果好,能够明显降低因此病症给养殖户带来的损失,具体为:
饲料中添加维生素C,或复合多维素,维持体内电解质平衡,以缓和应激反应。
早期限饲的方法,采取早期适量限饲可有效的减少以后的腹水。在肉鸡饲养的第三四周(15天~28天)期间减少15%喂料,28天以后恢复正常喂料时,采食量增加,可弥补前期亏重,出栏体重正常。减料方式可使用晚间定时熄灯或定时空槽,由此可减少腹水症的发生。
脲酶抑制剂,可大幅降低死亡率,其机理是给肉鸡饲喂脲酶抑制剂,既抑制了小肠和大肠中的脲酶活性,又降低了小肠和大肠内氨的含量,从而降低门脉排血器官的黏膜组织周转率与耗氧量,这样就有较多的氧气供机体利用,消除了造成腹水症及死亡的原动力。
碳酸氢钠呈碱性,可以降低肉鸡腹水症的发生率。在饲料中用于中和酸中毒情况,使血管扩张而使肺动脉降低,从而降低了腹水症的发病率
而且,通过添加防治药物,保护肝肺,护心补血,利尿逐水同时活血化瘀,同时抑菌,防治继发性疾病,大大降低了发病几率,减少养殖户损失。
具体实施方式:
例子1:
A肉鸡在15-28日龄期间内,饲料供应量减少15%;28日龄后恢复正常的饲料供应量,
B整个养殖期间保持鸡舍通风,减少鸡舍内部CO2和NH3的含量,
C日常喂食的饲料中磷含量不小于0.05%,盐含量不大于0.5%,尿酶抑制剂含量不小于0.13%,碳酸氢钠含量不小于1%,维生素C不小于0.5%;
D肉鸡在15-28日龄期间内,添加的防治药物的含量不小于3%,发病期间,添加的防治药物的含量不小于5%。
所述防治药物的组分为:葶苈子、大枣、黄连、栀子各80g,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶各50g,木通、生地、人参、麦冬、京大戟、赤小豆各40g,桔梗、炙甘草各30g。
饲料的组分为:玉米54-61%,豆粕27-32%,碳酸轻钙1-1.5%,石粉1-1.2%,食用油2-3%,鱼粉2-3%,麦麸3-5%,贝壳粉2-3%。
日常喂食的饲料中磷含量不小于0.05%添加的磷元素成分为过磷酸钙。
尿酶抑制剂优选为醋羟氨酸。
优选:
饲料:玉米54.2%,豆粕32%,碳酸轻钙1.2%,石粉1%,食用油2%,鱼粉3%,麦麸4%,贝壳粉2.6%。
辅料的添加量为均以饲料为参照基础。
例如,饲料基本料配置100kg,加入辅料,加入的辅料为过磷酸钙0.06kg,盐0.4kg,尿酶抑制剂0.15kg,碳酸氢钠1kg,维生素C0.6kg,防治药物3kg。
维生素C可以用复合多维素替代。
上述方法在即墨秦家养殖户使用养殖肉鸡,自鸡苗到成鸡出栏,养殖3500只肉鸡,腹水症的发病只数为253只,发病率仅为7.2%,253只中治愈227只,有效率89.7%。
例子2
A肉鸡在15-28日龄期间内,饲料供应量减少15%;28日龄后恢复正常的饲料供应量,
B整个养殖期间保持鸡舍通风,减少鸡舍内部CO2和NH3的含量,
C日常喂食的饲料中磷含量不小于0.05%,盐含量不大于0.5%,尿酶抑制剂含量不小于0.13%,碳酸氢钠含量不小于1%,维生素C不小于0.5%;
D肉鸡在15-28日龄期间内,添加的防治药物的含量不小于3%,发病期间,添加的防治药物的含量不小于5%。
所述防治药物的组分为:葶苈子、大枣、黄连、栀子各70g,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶各45g,木通、生地、人参、麦冬、京大戟、赤小豆各30g,桔梗、炙甘草各20g。
饲料的组分为:玉米54-61%,豆粕27-32%,碳酸轻钙1-1.5%,石粉1-1.2%,食用油2-3%,鱼粉2-3%,麦麸3-5%,贝壳粉2-3%。
日常喂食的饲料中磷含量不小于0.05%添加的磷元素成分为磷酸二氢钙。
尿酶抑制剂优选为醋羟氨酸。
优选:
饲料:玉米56%,豆粕30%,碳酸轻钙1.2%,石粉1.2%,食用油3%,鱼粉3%,麦麸3%,贝壳粉2.6%。
辅料的添加量为均以饲料为参照基础。
例如,饲料基本料配置100kg,加入辅料,加入的辅料为磷酸二氢钙0.06kg,盐0.4kg,尿酶抑制剂0.15kg,碳酸氢钠1kg,维生素C0.6kg,防治药物3.5kg。
维生素C可以用复合多维素替代。
上述方法在胶州张家养殖户使用养殖肉鸡,自鸡苗到成鸡出栏,养殖2000只肉鸡,腹水症的发病只数为120只,发病率仅为6%,120只中治愈104只,有效率86.7%。
例子3
A肉鸡在15-28日龄期间内,饲料供应量减少15%;28日龄后恢复正常的饲料供应量,
B整个养殖期间保持鸡舍通风,减少鸡舍内部CO2和NH3的含量,
C日常喂食的饲料中磷含量不小于0.05%,盐含量不大于0.5%,尿酶抑制剂含量不小于0.13%,碳酸氢钠含量不小于1%,维生素C不小于0.5%;
D肉鸡在15-28日龄期间内,添加的防治药物的含量不小于3%,发病期间,添加的防治药物的含量不小于5%。
所述防治药物的组分为:葶苈子、大枣、黄连、栀子各60g,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶各40g,木通、生地、人参、麦冬、京大戟、赤小豆各20g,桔梗、炙甘草各15g。
饲料的组分为:玉米54-61%,豆粕27-32%,碳酸轻钙1-1.5%,石粉1-1.2%,食用油2-3%,鱼粉2-3%,麦麸3-5%,贝壳粉2-3%。
日常喂食的饲料中磷含量不小于0.05%添加的磷元素成分为磷酸氢钙。
尿酶抑制剂优选为醋羟氨酸。
饲料:玉米61%,豆粕28%,碳酸轻钙1%,石粉1%,食用油2%,鱼粉2%,麦麸3%,贝壳粉2%。
辅料的添加量为均以饲料为参照基础。
例如,饲料基本料配置100kg,加入辅料,加入的辅料为磷酸氢钙0.06kg,盐0.4kg,尿酶抑制剂0.15kg,碳酸氢钠1kg,维生素C0.6kg,防治药物4kg。
维生素C可以用复合多维素替代。
上述方法在莱西陈家养殖户使用养殖肉鸡,自鸡苗到成鸡出栏,养殖3200只肉鸡,腹水症的发病只数为224只,发病率仅为7%,224只中治愈197只,有效率87.9%。
病理实验:
1、模型建立
选择300只4周龄-5周龄之间的肉鸡,体重差别小于10g,随机分为6组,每组50只,1-5组为实验组,6组为正常对照组。
实验组建模:
将1-5组置于狭小空间内,此空间内的CO2和NH3的含量为正常鸡舍的2倍,同时喂食采用高蛋白、高脂肪的高耗氧饲料,盐含量高于3%,饲料中无硒元素和维生素C、E,以及磷元素。提高空气中湿气度,并用福尔马林等刺激导致肺部缺氧而发生。持续10天后,
1-5组肉鸡表现精神不振,羽毛蓬乱,拉稀,腹部膨胀,两腿叉开,行为迟钝,呼吸困难,冠和肉垂呈紫红色,剖检可见鸡全身组织器官淤血、水肿,全身骨骼肌淤血、深红色。肺部充血、水肿,心包积液,心脏增大,肝脏充血、边缘变厚、覆有一层半胶冻样物,肾脏充血肿大,并有尿酸盐沉积,肠道广泛充血,腹腔中有纤维蛋白凝块,积液通常清亮呈棕红色。模型建立。
2、对比试验
1组喂食本发明的例子3,每只喂食50g。痊愈后去掉防治药物继续喂食本发明饲料。
2组喂食本发明的例子1,每只喂食50g。痊愈后去掉防治药物继续喂食本发明饲料。
3组喂食被发明的背景技术中的中药方剂用二丑、泽泻、木通、商陆根、苍术、猪苓、谷子、灯心草各500克,竹叶250克,共研细末,每只喂食1g。
4组单独使用氨苄青霉素,拌饲料喂食。
5组,抽取腹水后,进行2次1g/L亚硒酸钠0.1mL的肌肉注射,同时服用利尿剂。
6组为正常对照组。
上述各组比较效果如下:
组织学检查:
各组取心、肝、肺、脾、胃、肠、肾、大脑、胸腺、法氏囊等组织,用10%福尔马淋固定,常规石蜡切片,HE染色,镜检。
2 结果
1-5组中死亡的肉鸡腹部膨隆,触摸有波动感,腹部皮肤变薄发亮,严重的发红。剖开腹部,从腹腔中流出多量淡黄色或清亮透明的液体,有的混有纤维素沉积物;心脏肿大、变形、柔软,尤其右心房扩张显著。右心肌变薄,心肌色谈并带有白色条纹,心腔积有大量凝血块,肺动脉和主动脉极度扩张,管腔内充满血液。部分鸡心包积有淡黄色液体;肝脏肿大或萎缩、质硬,淤血、出血,胆囊肿大,突出肝表面,内充满胆汁;肺淤血、水肿,呈花斑状,质地稍坚韧,间质有灰白色条纹,切面流出多量带有小气泡的血样液体;脾呈暗红色,切面脾小体结构不清;肾稍肿,淤血、出血。脑膜血管怒张、充血;胃稍肿、淤血、出血;肠系膜及浆膜充血,肠粘膜有少量出血,肠壁水肿增厚。
治愈的1-2组与正常对照组体征基本一致。
3-5组中,心包积液扔有存在,胃部出血,肠粘膜出血症状仍有17%存在。
病死的1-5组中肾脏:肾小球充血,血管丛内皮细胞肿胀,肾小管上皮细胞肿胀,颗粒变性、空泡变性、脂肪变性甚至坏死,管腔中可见透明管型;间质水肿,疏松、血管充血,
治愈的1-2组与正常对照组体征基本一致。
3-5组中脂肪变性和管腔间质水肿有22%存在。
病死的1-5组脾脏:整个脾的淋巴细胞减少,脾小体缩少,髓窦中淤积大量红细胞及水肿液,髓索及脾小体淋巴细胞中也散在有红细胞,窦内皮细胞肿胀。
治愈的1-2组与正常对照组体征基本一致。
3-5组中淋巴细胞数量仍为低于正常值。
实验数据:沙门氏菌病等继发病原菌或某些病毒引起肺、心、肝病变,而导致大量腹水出现。
以针对沙门氏菌的抑制试验。
取3份粉剂各50g,分别装入500ml小烧杯,加入粉剂5倍重量的有机溶剂甲醇。氯仿、石油醚。室温下浸泡3天,过滤浓缩至膏状,称取一定量提取物加吐温80做乳化剂,4摄氏度保存,
采用生长速率法,用打孔器取6mm菌落边缘旺盛的菌种,放在加药的PDA平板上培养,以培养基加等量的无菌水做对照,每次重复3次,置于25摄氏度培养,用十字交叉法测每个菌落直径,以平均值代表菌落的直径,求出抑制细菌的生长率=(对照菌落直径-处理菌落直径)/(对照菌落直径-0.6)×100%。
将3种有机溶剂的提取物制成终浓度为1mg/ml的提取液的PEA培养基,取预先配制好的悬浮液10ul,接种到直径为9cm的培养皿中央,通涂布器涂抹均匀,在25摄氏度培养箱中培养48小时,计算抑制细菌的生长率。
通过上述数据可以看出本发明的防治药物对沙门氏菌即腹水的继发性致病菌具有较好的抑制作用
毒性对大鼠的实验:
急性经口(LD50)〉500mg/kg,
急性经皮(LD 50)〉2000mg/kg,
属于低毒。
本发明配比简单,使用方便,预防和防治肉鸡腹水症效果好,能够明显降低因此病症给养殖户带来的损失,饲料中添加维生素C,或复合多维素,维持体内电解质平衡,以缓和应激反应。早期限饲的方法,采取早期适量限饲可有效的减少以后的腹水。在肉鸡饲养的第三四周(15天~28天)期间减少15%喂料,28天以后恢复正常喂料时,采食量增加,可弥补前期亏重,出栏体重正常。减料方式可使用晚间定时熄灯或定时空槽,由此可减少腹水症的发生。
脲酶抑制剂,可大幅降低死亡率,其机理是给肉鸡饲喂脲酶抑制剂,既抑制了小肠和大肠中的脲酶活性,又降低了小肠和大肠内氨的含量,从而降低门脉排血器官的黏膜组织周转率与耗氧量,这样就有较多的氧气供机体利用,消除了造成腹水症及死亡的原动力。
碳酸氢钠呈碱性,可以降低肉鸡腹水症的发生率。在饲料中用于中和酸中毒情况,使血管扩张而使肺动脉降低,从而降低了腹水症的发病率
而且,通过添加防治药物,保护肝肺,护心补血,利尿逐水同时活血化瘀,同时抑菌,防治继发性疾病,大大降低了发病几率,减少养殖户损失。
Claims (1)
1.一种肉鸡的养殖所使用的药物的制造方法,其特征在于,按如下步骤操作:将葶苈子、大枣、黄连、栀子,蒲黄、郁金、泽兰、香薷、浮萍、鸭趾草、木芙蓉叶,木通、生地、人参、麦冬、京大戟、赤小豆,桔梗、炙甘草使用水浸提法浸提三次,三次浸提液合并后,蒸煮至粘稠状,加入改性淀粉和羟甲基纤维素、矫味剂;改性淀粉和羟甲基纤维素、矫味剂的质量比为2:1:0.5,改性淀粉、羟甲基纤维素与矫味剂的质量和为防治药物原料的质量的2-3%;
干燥后呈粉剂并过80目筛,过筛后的粉剂经过紫外照射消毒10秒后,加入氨苄青霉素,加入的氨苄青霉素的质量为粉剂质量的1-2%,混合均匀后制得本发明所用的防治药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410496358.8A CN104258282A (zh) | 2014-09-25 | 2014-09-25 | 一种肉鸡的养殖所使用的药物的制造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410496358.8A CN104258282A (zh) | 2014-09-25 | 2014-09-25 | 一种肉鸡的养殖所使用的药物的制造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104258282A true CN104258282A (zh) | 2015-01-07 |
Family
ID=52149939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410496358.8A Pending CN104258282A (zh) | 2014-09-25 | 2014-09-25 | 一种肉鸡的养殖所使用的药物的制造方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104258282A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105535198A (zh) * | 2016-01-29 | 2016-05-04 | 青岛信诺邦生物科技有限公司 | 一种治疗家禽心包积液的中药组合物 |
-
2014
- 2014-09-25 CN CN201410496358.8A patent/CN104258282A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105535198A (zh) * | 2016-01-29 | 2016-05-04 | 青岛信诺邦生物科技有限公司 | 一种治疗家禽心包积液的中药组合物 |
CN105535198B (zh) * | 2016-01-29 | 2020-03-31 | 青岛信诺邦生物科技有限公司 | 一种治疗家禽心包积液的中药组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103039745B (zh) | 一种产蛋麻鸭的日粮精饲料及其制备方法 | |
CN103689296B (zh) | 妊娠后期和哺乳期的母羊饲料及其制备方法 | |
CN104054972B (zh) | 一种用于饲养河蟹的饲料 | |
CN103749982B (zh) | 用于提高产鸡蛋产量的饲料、中药添加剂和制备方法 | |
CN102940155B (zh) | 一种樱桃谷鸭的雏鸭饲料及其制备方法 | |
CN104082540B (zh) | 保健鸡蛋用饲料 | |
CN104054973B (zh) | 一种用于提高鲤鱼免疫功能的饲料 | |
CN102845638A (zh) | 一种防治禽流感的鸭饲料及其中药添加剂 | |
CN103564267A (zh) | 一种防治山瑞鳃腺炎病的饲料 | |
CN103392927A (zh) | 一种提高种公猪精液品质的猪饲料及其制备方法 | |
CN105384562A (zh) | 一种袖珍菇培养基 | |
CN104247889A (zh) | 一种肉鸡的养殖所使用的饲料 | |
CN104222651A (zh) | 一种肉鸡的养殖防鸡禽腹水使用的饲料的制造方法 | |
CN105104874A (zh) | 一种生态龟饲料 | |
CN104082539B (zh) | 保健鸡蛋用添加剂 | |
CN104222652A (zh) | 一种肉鸡的养鸡方法 | |
CN106343271A (zh) | 一种肉龟饲料 | |
CN107439839B (zh) | 一种提高蛋鹑产蛋性能的饲料添加剂及其制备方法 | |
CN104258282A (zh) | 一种肉鸡的养殖所使用的药物的制造方法 | |
CN104225482A (zh) | 一种肉鸡养殖防腹水所使用的药物 | |
CN105981934A (zh) | 富硒肉兔饲料及其饲养方法 | |
CN104247695A (zh) | 一种肉鸡的养殖方法 | |
CN107996886A (zh) | 一种对虾高蛋白饲料及其制备方法 | |
CN114470084A (zh) | 环保高效防治罗非鱼白便的组合物及其制备方法和应用 | |
CN104288676A (zh) | 一种肉鸡的养殖所使用的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150107 |
|
WD01 | Invention patent application deemed withdrawn after publication |